Avacta Group PLC has released its block listing six-monthly return, in accordance with the AIM Rules for Companies. The company has reported on its existing block admission arrangements for the EMI and LTIP schemes. For the EMI scheme, the balance of unallotted securities stands at 911,730, with an increase of 113,808 since the last return. Meanwhile, for the LTIP scheme, the balance of unallotted securities is 11,777,257, reflecting an increase of 6,500,000. The number of securities issued/allotted under the schemes during the period was 108,724 for the EMI scheme and 2,058,000 for the LTIP scheme.

Avacta Group PLC is a UK-based life sciences company with a focus on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company has two divisions: Avacta Therapeutics, a clinical-stage oncology biotech division developing novel, highly targeted cancer drugs, and Avacta Diagnostics, which aims to support healthcare professionals and broaden access to diagnostics. Avacta utilizes two proprietary platforms, pre|CISION™ and Affimer®, to develop its products.

The pre|CISION™ platform is designed to activate peptide drug conjugates and antibody/Affimer® drug conjugates in the tumor microenvironment, reducing systemic exposure and toxicity, and allowing for optimized dosing to deliver better patient outcomes. The company's focus on innovative, targeted oncology drugs and powerful diagnostics underscores its commitment to advancing healthcare and addressing critical medical needs.

For further information, interested parties can contact Avacta Group PLC directly or its appointed brokers and advisors. The company's leadership team, including the CEO, CFO, and Group Communications Director, can also be reached for additional details. The company's website and contact information for its appointed brokers and advisors are provided for reference.